title: Prognostic Impact of the ABCC11/MRP8 Polymorphism in Adjuvant Oral Chemotherapy with S-1 for Non-Small Cell Lung Cancer.
abstract: BACKGROUND
  Postoperative 1-year administration of S-1, an oral derivative of 5-fluorouracil (5-FU), was shown to be feasible in lung cancer. The 5-year survival rates of postoperative patients treated with S-1 adjuvant chemotherapy and the prognostic impact of clinicopathological factors were examined.
  
  
  METHODS
  The data of 50 patients with curatively resected pathological stage IB to IIIA non-small cell lung cancer, who were treated with S-1 postoperatively, were analyzed. The prognostic impacts of 22 clinicopathological factors including expressions of the 5-FU pathway enzymes were evaluated. A single-nucleotide polymorphism (SNP), i.e. 538G>A (rs17822931), of ABCC11/MRP8, which encodes a 5-FU excretion enzyme that is known as an earwax type determinant, was also evaluated.
  
  
  RESULTS
  The 5-year overall and relapse-free survival rates were 72.5 and 67.5%, respectively. A performance status ≥ 1, lymphatic vessel invasion, blood vessel invasion, and the A/A type of SNP538, which is responsible for the dry earwax type, were significantly associated with shorter relapse-free survivals. In 34 patients who showed a relative performance of 70% or more for chemotherapy, multivariate survival analysis indicated significant hazard ratios only for the A/A type of SNP538 (p = 0.007).
  
  
  CONCLUSIONS
  S-1 has sufficient power as adjuvant chemotherapy. However, its effect might be small in the dry earwax type patient group in an adjuvant setting.
authors.forename: Tomoshi
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: Junichi
authors.initials: J
authors.lastname: Arai
authors.forename: Keitaro
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Takuro
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Sumihisa
authors.initials: S
authors.lastname: Honda
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Tagawa
authors.forename: Akihiro
authors.initials: A
authors.lastname: Nakamura
authors.forename: Hideki
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Isao
authors.initials: I
authors.lastname: Sano
authors.forename: Shinji
authors.initials: S
authors.lastname: Akamine
authors.forename: Masashi
authors.initials: M
authors.lastname: Muraoka
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hisano
authors.forename: Naoya
authors.initials: N
authors.lastname: Yamasaki
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nagayasu
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000235:genetics* / Q000378:metabolism; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage*; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D016019:Survival Analysis; D005641:Tegafur / Q000008:administration & dosage*
chemical_list: C435500:ABCC11 protein, human; D018528:ATP-Binding Cassette Transporters; D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid